- In January 2021, Roche signed a Global Business Partnership Agreement (GBP) with Sysmex to enhance hematology testing solutions. The partnership aims to leverage IT systems, improving clinical decision-making and customer experience. This collaboration has evolved over time, continuously introducing hematology testing innovations to laboratories worldwide, fostering advancements in the healthcare sector
- In December 2020, Abbott launched its next-generation glucose monitoring technology, the FreeStyle Libre 2. Approved by Health Canada, this sensor-based device is designed for both adults and children (4 years and older) with diabetes. The technology offers real-time glucose monitoring, allowing patients to manage their condition more effectively and safely, enhancing diabetes care
- In December 2020, Bio-Rad Laboratories expanded its joint marketing agreement with Siemens Healthineers. Under the new terms, Bio-Rad will provide quality control products and Unity Quality Control data management solutions for Siemens Healthineers' Atellica Solution platforms. This expansion strengthens both companies' position in the clinical diagnostics market, enhancing quality assurance and data management across laboratories
- In November 2020, Medtronic introduced InPen, integrated with real-time Guardian Connect CGM data. This device is the first FDA-cleared smart insulin pen for patients on multiple daily injections (MDI). InPen provides accurate insulin dosing, helps manage blood sugar levels, and offers real-time feedback, revolutionizing diabetes management for individuals requiring consistent insulin therapy
- In October 2020, Bio-Rad Laboratories launched the CFX Opus 96 and CFX Opus 384 Real-time PCR Systems. These advanced systems, combined with BR.io—a cloud-based connectivity and data management platform—enhance laboratory efficiency in molecular biology research and diagnostics. The launch signifies Bio-Rad’s continued commitment to improving scientific research and clinical diagnostics with cutting-edge technology
- In September 2020, Medtronic received FDA approval for its MiniMed 770G hybrid closed-loop insulin pump system. The system incorporates SmartGuard technology, which enhances diabetes management by automatically adjusting insulin delivery. It features smartphone connectivity and caters to a broader age range, starting at 2 years old, offering greater convenience and control for diabetes patients
- In June 2020, Abbott and Tandem Diabetes Care finalized an agreement to combine Abbott’s continuous glucose monitoring (CGM) technology with Tandem’s insulin delivery systems. This collaboration aims to offer integrated diabetes solutions, enhancing patient care by providing more accurate, seamless monitoring and insulin delivery options. It promises to improve overall diabetes management for patients
